10 reports of this reaction
4.1% of all GUAIFENESIN AND DEXTROMETHORPHAN HBR reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for GUAIFENESIN AND DEXTROMETHORPHAN HBR, manufactured by CVS Pharmacy. There are 10 FDA adverse event reports linking GUAIFENESIN AND DEXTROMETHORPHAN HBR to DYSPNOEA. This represents approximately 4.1% of all 244 adverse event reports for this drug.
Patients taking GUAIFENESIN AND DEXTROMETHORPHAN HBR who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among GUAIFENESIN AND DEXTROMETHORPHAN HBR users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for GUAIFENESIN AND DEXTROMETHORPHAN HBR:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 10 FDA reports for GUAIFENESIN AND DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 4.1% of all adverse event reports for GUAIFENESIN AND DEXTROMETHORPHAN HBR, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking GUAIFENESIN AND DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.